Study results demonstrate GBA1-targeted allosteric regulators increase GCase protein levels, reduce the production of inflammatory cytokines, and improve key lysosomal functions BETHESDA, Md., Feb. 08, …
BETHESDA, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming and accelerating drug discovery …
Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable BETHESDA, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) …
– Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable – – 18th Annual WORLDSymposium – – AD/PD™ 2022 – BETHESDA, …
BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that …
BETHESDA, Md., Dec. 28, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing …
Data Show Statistically Significant Increases in GALC Enzyme and Depletion of Toxic Substrate Psychosine BETHESDA, Md., Dec. 07, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: …
BETHESDA, Md., Dec. 01, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites …
BETHESDA, Md., Dec. 01, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites …
Brain-penetrant structurally targeted allosteric regulators for glucocerebrosidase (GCase) show promising in vivo pharmacological activity in Parkinson’s Disease animal model BETHESDA, Md., Nov. 11, 2021 (GLOBE …
Study results demonstrate first small molecule approach to significantly reduce phosphorylated and aggregated -synuclein and increase GCase protein levels with transport to the lysosomes in …
In-Person Dates: November 16th-17th Virtual Dates: November 18th-19th BETHESDA, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), …
– The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Webinars – – Society of Neuroscience 50th Anniversary Meeting – BETHESDA, Md., Oct. 28, 2021 (GLOBE …
Dr. Luca Benatti to Chair SAB BETHESDA, Md., Oct. 26, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “company”), a biotechnology …
BETHESDA, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing …
Conference Dates: September 27th-30th BETHESDA, Md., Sept. 23, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused …
– Conference Dates: September 20th-23rd – BETHESDA, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology …
BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing …
GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters — Study results demonstrate an increase in GCase protein levels with transport to …
BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing …
Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology — Granted Two Patents for Compounds that Stabilize G-Case for Gaucher’s Disease and other Synucleinopathies …
BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and …
Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage Diseases BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) — …
BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and …
BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and …
Completed successful initial public offering and raised $46 million in gross proceeds — Appointed four new independent board of directors to strengthen leadership team — …
Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of …
BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and …
Abstract highlighting Gain’s STAR candidate for Parkinson’s disease selected as one of the 10 Best Abstracts at the conference BETHESDA, Md., April 22, 2021 (GLOBE …
Collaboration to use Gain’s proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets BETHESDA, Md., April 20, …